Received Apr 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Z011862 | OT |
No additional AE reported; PROQUAD was administered to an adult patient; This spontaneous report was received from a Nurse and referred to a 34-year-old patient of unknown gender. Information regarding the patient's concurrent conditions, medical history, or concomitant medications was not provided. On 23-Mar-2026, the adult patient was vaccinated with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) powder and solvent for solution for injection/infusion (valid lot number: Z011862; expiration date reported and confirmed as 13-Jan-2027; dose, route of administration and anatomical location not provided) for prophylaxis; the suspect vaccine was reconstituted with sterile diluent (Hollister-Stier sterile diluent) (dose, lot number and expiration date were not reported). The nurse reported that she was not the person that administered the product and was unsure if the product was administered because it was confused with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (MMR II) or they intended to administer Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (Product administered to patient of inappropriate age). She reported as far as she can tell this patient had not previously been vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (MMR II). No additional adverse event was reported (no adverse event). This is one of several reports received from the same reporter.
DILUENT MRK